Page last updated: 2024-10-20
uracil and Leukopenia
uracil has been researched along with Leukopenia in 38 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
Leukopenia: A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "We performed a controlled study to compare the response to cyclophosphamide (CPA), adriamycin (ADM), and fluorouracil (5-FU) (CAF therapy) with that to uracil-tegafur (UFT) plus tamoxifen (TAM) (UFT+TAM therapy), when given as postoperative adjuvant therapy to women with breast cancer." | 9.12 | [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant set ( Inaji, H; Koyama, H; Mori, T; Nakao, K; Oka, T; Oshima, A; Ozawa, K; Saito, Y; Sakai, K; Senoo, T; Taguchi, T; Terasawa, T, 2006) |
| "The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer." | 8.87 | Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011) |
| "The RECOURSE trial showed clinical efficacy for trifluridine/tipiracil for refractory metastatic colorectal cancer patients." | 7.88 | Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands. ( Baars, A; Beerepoot, LV; Boot, H; Creemers, GJ; de Groot, JW; Hamberg, P; Jansen, RL; Kapiteijn, E; Koopman, M; Kwakman, JJM; Los, M; Opdam, FL; Punt, CJA; Schut, H; Sommeijer, DW; van Meerten, E; van Rooijen, JM; Vestjens, JH; Vink, G; Vulink, AJE, 2018) |
| "Standard chemotherapy for advanced biliary tract cancer has not been established." | 6.72 | Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. ( Funakoshi, A; Furuse, J; Horikawa, Y; Ikeda, M; Ishii, H; Mizuno, N; Morizane, C; Nagase, M; Nakachi, K; Okusaka, T; Ueno, H; Yamao, K, 2006) |
| "We performed a controlled study to compare the response to cyclophosphamide (CPA), adriamycin (ADM), and fluorouracil (5-FU) (CAF therapy) with that to uracil-tegafur (UFT) plus tamoxifen (TAM) (UFT+TAM therapy), when given as postoperative adjuvant therapy to women with breast cancer." | 5.12 | [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant set ( Inaji, H; Koyama, H; Mori, T; Nakao, K; Oka, T; Oshima, A; Ozawa, K; Saito, Y; Sakai, K; Senoo, T; Taguchi, T; Terasawa, T, 2006) |
| " This phase II study assessed the response rate and toxicity profile of the combination of epirubicin, cisplatin and UFT in patients with metastatic adenocarcinoma of the stomach." | 5.11 | A phase II study of epirubicin, cisplatin and uracil-tegafur for advanced gastric carcinoma. ( Byun, JH; Choi, MG; Chung, IS; Hong, YS; Kang, JH; Kim, KW; Lee, KS; Lee, MA; Moon, DH; Park, SY; Shim, BY; Woo, IS, 2005) |
| "Thirty-nine patients with locally advanced or metastatic gastric carcinoma received oral UFT (tegafur and uracil) plus leucovorin." | 5.08 | A phase II trial. Oral UFT and leucovorin in patients with advanced gastric carcinoma. ( Kim, BS; Kim, JG; Kim, JS; Kim, YH; Park, YT; Shin, SW, 1997) |
| "The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer." | 4.87 | Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011) |
| "Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy." | 4.40 | Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023) |
| "The RECOURSE trial showed clinical efficacy for trifluridine/tipiracil for refractory metastatic colorectal cancer patients." | 3.88 | Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands. ( Baars, A; Beerepoot, LV; Boot, H; Creemers, GJ; de Groot, JW; Hamberg, P; Jansen, RL; Kapiteijn, E; Koopman, M; Kwakman, JJM; Los, M; Opdam, FL; Punt, CJA; Schut, H; Sommeijer, DW; van Meerten, E; van Rooijen, JM; Vestjens, JH; Vink, G; Vulink, AJE, 2018) |
| "Concomitant treatment with 5-fluorouracil (5-FU) and Leucovorin (LV) is positioned as the standard chemotherapy against colorectal cancer." | 3.72 | [Home chemotherapy by concomitant UFT + Leucovorin (po.) in postoperative colorectal cancer patients assessed with Dukes D and curability C colorectal cancer]. ( Anazawa, S; Hirai, K; Kawahara, H; Ogawa, M; Sakuyama, T; Sato, K; Takao, Y; Yamazaki, Y; Yokoyama, M, 2004) |
| "Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity." | 3.68 | Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity. ( Calabresi, P; Chu, SH; Darnowski, JW; Falcone, A; St Clair, MH; Wiemann, MC, 1990) |
| " Major adverse events were neutropenia, leukopenia, anemia, and nausea." | 2.82 | Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors. ( Bando, H; Doi, T; Fuse, N; Goto, K; Ito, Y; Kojima, T; Mukai, H; Naito, Y; Ohtsu, A; Yamazaki, T; Yoshino, T, 2016) |
| "Standard chemotherapy for advanced biliary tract cancer has not been established." | 2.72 | Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. ( Funakoshi, A; Furuse, J; Horikawa, Y; Ikeda, M; Ishii, H; Mizuno, N; Morizane, C; Nagase, M; Nakachi, K; Okusaka, T; Ueno, H; Yamao, K, 2006) |
| " Administration of more than 2 courses was attempted for each patient, with the same dosage levels at all 3 scheduled steps." | 2.71 | [Phase I study of gemcitabine (GEM) and UFT combination chemotherapy for unresectable/recurrent pancreatic cancer]. ( Dono, K; Maruhashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Takahashi, Y; Tujie, M; Umeshita, K, 2004) |
| ") gemcitabine (GEM) at low dose plus oral chemotherapy with uracil-tegafur (UFT) and cyclophosphamide (CPA) in combination with radiotherapy (RT) against recurrent and advanced pancreatic cancers." | 2.71 | Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer. ( Endo, S; Hashimoto, K; Higami, T; Itakura, M; Koike, M; Maruyama, R; Nio, Y; Tsuji, M; Yamaguchi, K; Yano, S, 2005) |
| "Uracil-tegafur (UFT) has been reported to have broad antitumor activity in a variety of malignancies." | 2.71 | A phase II trial of Uracil-tegafur (UFT) in patients with advanced biliary tract carcinoma. ( Furuse, J; Ikeda, M; Ishii, H; Morizane, C; Okusaka, T; Ueno, H, 2005) |
| "Forty-eight patients with unresectable gastric cancer were enrolled for a randomized trial of FP (n = 24) vs FEP (n = 24) combination chemotherapy with respect to their effects on survival period." | 2.68 | [Combination chemotherapy with FP versus FEP in patients with advanced gastric cancer. Research group of gastric cancer chemotherapy]. ( Horiuchi, Y; Ina, K; Iwase, H; Kaneko, H; Kuroiwa, A; Kusugami, K; Morise, K; Oka, Y; Shinoda, M; Suga, S, 1995) |
| "Thirty-four patients with advanced gastric cancer were treated with combination chemotherapy employing Tegafur-Uracil (UFT), etoposide, Adriamycin, and Cisplatinum (CDDP) (UFT-EAP therapy)." | 2.67 | Combination chemotherapy with Tegafur. Uracil (UFT), etoposide, adriamycin and cisplatinum (UFT-EAP) for advanced gastric cancer. ( Chin, K; Hattori, T; Hayakawa, M; Maeda, H; Morise, K; Morooka, Y; Saito, H; Sugihara, M, 1994) |
| "Although there are many randomized clinical trials of late course accelerated hyperfractionated radiotherapy (LCAHFR) combined with FP chemotherapy for esophageal cancer, the efficacy and toxicity are controversial." | 2.46 | Meta-analysis of late course accelerated hyperfractionated radiotherapy combined with FP chemotherapy for esophageal carcinoma. ( Gao, XS; Li, XY; Liu, CX, 2010) |
| " 5'-DFUR was less toxic to immune organs and the functions than those by other fluorinated pyrimidines." | 1.27 | [Antitumor activity and toxicity to the immune system and intestine, of the fluorinated pyrimidines FUra, 5'-DFUR, tegafur and UFT]. ( Fujimoto, K; Ishitsuka, H; Matsuura, N; Miwa, M; Ninomiya, Y; Ryu, M, 1988) |
Research
Studies (38)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (26.32) | 18.7374 |
| 1990's | 11 (28.95) | 18.2507 |
| 2000's | 12 (31.58) | 29.6817 |
| 2010's | 4 (10.53) | 24.3611 |
| 2020's | 1 (2.63) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Kwakman, JJM | 1 |
| Vink, G | 1 |
| Vestjens, JH | 1 |
| Beerepoot, LV | 1 |
| de Groot, JW | 1 |
| Jansen, RL | 1 |
| Opdam, FL | 1 |
| Boot, H | 1 |
| Creemers, GJ | 1 |
| van Rooijen, JM | 1 |
| Los, M | 1 |
| Vulink, AJE | 1 |
| Schut, H | 1 |
| van Meerten, E | 1 |
| Baars, A | 1 |
| Hamberg, P | 1 |
| Kapiteijn, E | 1 |
| Sommeijer, DW | 1 |
| Punt, CJA | 1 |
| Koopman, M | 1 |
| Yoshino, T | 1 |
| Kojima, T | 1 |
| Bando, H | 1 |
| Yamazaki, T | 1 |
| Naito, Y | 1 |
| Mukai, H | 1 |
| Fuse, N | 1 |
| Goto, K | 1 |
| Ito, Y | 1 |
| Doi, T | 1 |
| Ohtsu, A | 1 |
| Bin, Q | 1 |
| Li, J | 1 |
| Liao, C | 1 |
| Cao, Y | 1 |
| Gao, F | 1 |
| Liu, CX | 1 |
| Li, XY | 1 |
| Gao, XS | 1 |
| Chen, JS | 1 |
| Yang, TS | 1 |
| Lin, YC | 1 |
| Jan, YY | 1 |
| BUTOMO, NV | 1 |
| SHCHERBAKOV, NI | 1 |
| MOROZOVA, EN | 1 |
| WOLBERG, WH | 1 |
| CURRERI, AR | 1 |
| VIETTI, TJ | 1 |
| BERRY, DH | 1 |
| FERNBACH, DJ | 1 |
| LUSHER, J | 1 |
| SUTOW, WW | 1 |
| KUSTOV, VV | 1 |
| Nakamori, S | 1 |
| Tujie, M | 1 |
| Takahashi, Y | 1 |
| Maruhashi, S | 1 |
| Miyamoto, A | 1 |
| Nagano, H | 1 |
| Dono, K | 1 |
| Umeshita, K | 1 |
| Sakon, M | 1 |
| Monden, M | 1 |
| Watanabe, O | 1 |
| Shimizu, T | 1 |
| Imamura, H | 1 |
| Kinoshita, J | 1 |
| Okabe, T | 1 |
| Ogawa, K | 1 |
| Haga, S | 1 |
| Sakuyama, T | 1 |
| Yokoyama, M | 1 |
| Ogawa, M | 1 |
| Takao, Y | 1 |
| Sato, K | 1 |
| Kawahara, H | 1 |
| Anazawa, S | 1 |
| Yamazaki, Y | 1 |
| Hirai, K | 1 |
| Woo, IS | 1 |
| Moon, DH | 1 |
| Shim, BY | 1 |
| Lee, MA | 1 |
| Byun, JH | 1 |
| Kim, KW | 1 |
| Kang, JH | 1 |
| Choi, MG | 1 |
| Chung, IS | 1 |
| Hong, YS | 1 |
| Park, SY | 1 |
| Lee, KS | 1 |
| Nio, Y | 1 |
| Hashimoto, K | 1 |
| Yano, S | 1 |
| Itakura, M | 1 |
| Koike, M | 1 |
| Yamaguchi, K | 1 |
| Endo, S | 1 |
| Tsuji, M | 1 |
| Higami, T | 1 |
| Maruyama, R | 1 |
| Ikeda, M | 2 |
| Okusaka, T | 2 |
| Ueno, H | 2 |
| Morizane, C | 2 |
| Furuse, J | 2 |
| Ishii, H | 2 |
| Sadahiro, S | 1 |
| Mitomi, T | 1 |
| Noto, T | 1 |
| Kumada, K | 1 |
| Hiki, Y | 1 |
| Yamakawa, T | 1 |
| Amano, T | 1 |
| Oki, S | 1 |
| Otani, Y | 1 |
| Oka, H | 1 |
| Takahashi, T | 1 |
| Takemiya, S | 1 |
| Nishiyama, K | 1 |
| Yamamura, T | 1 |
| Tsuchiya, S | 1 |
| Ogawa, N | 1 |
| Akasu, T | 1 |
| Moriya, Y | 1 |
| Ohashi, Y | 1 |
| Yoshida, S | 1 |
| Shirao, K | 1 |
| Kodaira, S | 1 |
| Ishida, H | 1 |
| Akita, H | 1 |
| Watanabe, Y | 1 |
| Nakaguchi, K | 1 |
| Kabuto, T | 1 |
| Funakoshi, A | 1 |
| Yamao, K | 1 |
| Nagase, M | 1 |
| Nakachi, K | 1 |
| Horikawa, Y | 1 |
| Mizuno, N | 1 |
| Inaji, H | 1 |
| Sakai, K | 1 |
| Oka, T | 1 |
| Ozawa, K | 1 |
| Saito, Y | 1 |
| Senoo, T | 1 |
| Taguchi, T | 1 |
| Terasawa, T | 1 |
| Nakao, K | 1 |
| Mori, T | 1 |
| Koyama, H | 1 |
| Oshima, A | 1 |
| Sato, A | 1 |
| Hasegawa, K | 1 |
| Kurihara, M | 2 |
| Takahashi, M | 1 |
| Akazawa, S | 1 |
| Fukuyama, Y | 1 |
| Koizumi, W | 1 |
| Hayakawa, M | 3 |
| Sasai, T | 1 |
| Kimura, K | 1 |
| Sanchiz, F | 1 |
| Milla, A | 1 |
| Shinoda, M | 1 |
| Morise, K | 3 |
| Kusugami, K | 1 |
| Iwase, H | 1 |
| Ina, K | 1 |
| Kaneko, H | 1 |
| Horiuchi, Y | 1 |
| Kuroiwa, A | 1 |
| Suga, S | 1 |
| Oka, Y | 1 |
| Chin, K | 1 |
| Sugihara, M | 1 |
| Morooka, Y | 1 |
| Maeda, H | 1 |
| Hattori, T | 1 |
| Saito, H | 1 |
| Ono, T | 1 |
| Komatsu, M | 1 |
| Hoshino, T | 1 |
| Ishii, T | 1 |
| Fujii, K | 1 |
| Ohshima, S | 1 |
| Mikami, K | 1 |
| Masamune, O | 1 |
| Fukuda, T | 1 |
| Abad, A | 1 |
| Navarro, M | 1 |
| Sastre, J | 1 |
| Marcuello, E | 1 |
| Aranda, E | 1 |
| Gallén, M | 1 |
| Fernandez-Martos, C | 1 |
| Martín, C | 1 |
| Diaz-Rubio, E | 1 |
| Ichinose, Y | 1 |
| Yano, T | 1 |
| Kudoh, S | 1 |
| Yoshimori, K | 1 |
| Morikawa, T | 1 |
| Kuba, M | 1 |
| Niitani, H | 1 |
| Kim, YH | 1 |
| Shin, SW | 1 |
| Kim, BS | 1 |
| Park, YT | 1 |
| Kim, JG | 1 |
| Kim, JS | 1 |
| Calabresi, P | 2 |
| Falcone, A | 2 |
| St Clair, MH | 1 |
| Wiemann, MC | 1 |
| Chu, SH | 2 |
| Darnowski, JW | 2 |
| Ruprecht, RM | 1 |
| Brunetti, I | 1 |
| Sakai, T | 1 |
| Thin, K | 1 |
| Ando, T | 1 |
| Kokubu, K | 1 |
| Akatsuka, Y | 1 |
| Sato, Y | 1 |
| Tahara, H | 1 |
| Kuwahara, Y | 1 |
| Ninomiya, Y | 1 |
| Ryu, M | 1 |
| Matsuura, N | 1 |
| Fujimoto, K | 1 |
| Miwa, M | 1 |
| Ishitsuka, H | 1 |
| Largiadèr, F | 1 |
| Kholodnyi, MD | 1 |
| Mindlin, SS | 1 |
| Krooth, RS | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of UFT Compared With Surgery Alone in Patients With Dukes C Colorectal Cancer (NSAS-CC)[NCT00152230] | Phase 3 | 900 participants (Anticipated) | Interventional | 1996-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Reviews
3 reviews available for uracil and Leukopenia
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans | 2011 |
Meta-analysis of late course accelerated hyperfractionated radiotherapy combined with FP chemotherapy for esophageal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bronchitis; Carcinoma, Squamous Cell | 2010 |
Trials
20 trials available for uracil and Leukopenia
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors.
Topics: Aged; Anemia; Antineoplastic Agents; Area Under Curve; Asian People; Biological Availability; Cross- | 2016 |
A phase II trial of tegafur-uracil plus leucovorin (LV) in the treatment of advanced biliary tract carcinomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neo | 2003 |
[Phase I study of gemcitabine (GEM) and UFT combination chemotherapy for unresectable/recurrent pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; D | 2004 |
[Clinical usefulness of UFT and cyclophosphamide as salvage chemotherapy for patients with metastatic breast cancer].
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; | 2004 |
A phase II study of epirubicin, cisplatin and uracil-tegafur for advanced gastric carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Prot | 2005 |
Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therap | 2005 |
A phase II trial of Uracil-tegafur (UFT) in patients with advanced biliary tract carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Drug Adm | 2005 |
[Multicenter comparative study of the recurrence-inhibitory effect of oral fluoropyrimidine drugs in patients with colorectal cancer following curative resection].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Pr | 2005 |
Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Chemot | 2006 |
Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; | 2006 |
[A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant set
Topics: Anorexia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Ne | 2006 |
[Combination chemotherapy with tegafur-uracil (UFT) and cisplatin (CDDP) for advanced gastric cancer. UFTP Study Group].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug A | 1995 |
Tegafur-uracil (UFT) plus folinic acid in advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Humans; L | 1994 |
[Combination chemotherapy with FP versus FEP in patients with advanced gastric cancer. Research group of gastric cancer chemotherapy].
Topics: Adenocarcinoma; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Admi | 1995 |
Combination chemotherapy with Tegafur. Uracil (UFT), etoposide, adriamycin and cisplatinum (UFT-EAP) for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; | 1994 |
A preliminary report of a phase II trial. UFT plus oral folinic acid as therapy for metastatic colorectal cancer in older patients. Spanish Group for the Treatment of Gastrointestinal Tumors (TTd Group).
Topics: Aged; Aged, 80 and over; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopl | 1997 |
UFT plus cisplatin in advanced non-small-cell lung cancer: interim analysis of 67 patients.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cispla | 1997 |
UFT plus cisplatin for advanced gastric cancer.
Topics: Adolescent; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrh | 1997 |
A phase II trial. Oral UFT and leucovorin in patients with advanced gastric carcinoma.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Diarrhea; Drug Co | 1997 |
Other Studies
16 other studies available for uracil and Leukopenia
| Article | Year |
|---|---|
Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2018 |
[Application of pentoxyl and sodium nucleinate on post-irradiation leukopenia].
Topics: Leukocyte Count; Leukopenia; Nucleic Acids; Pentoxyl; Radiation; Uracil | 1957 |
[The effect of pentoxyl on the lipids of the bone marrow of rabbits in experimental leukopenia].
Topics: Animals; Bone Marrow; Leukocyte Disorders; Leukopenia; Lipid Metabolism; Lipids; Mechlorethamine; Ni | 1961 |
Toxicity studies of 5-fluorouracil used as an adjunct to surgery.
Topics: Agranulocytosis; Fluorouracil; Humans; Leukopenia; Surgical Procedures, Operative; Uracil | 1960 |
URACIL MUSTARY THERAPY IN METASTATIC WILMS'S TUMOR.
Topics: Anemia; Child; Drug Therapy; Leukopenia; Nausea; Neoplasm Metastasis; Nitrogen Mustard Compounds; Th | 1964 |
[Result of pentoxyl therapy of leukopenia caused by intensive roentgenologic irradiation in syringomyelia and myasthenia].
Topics: Humans; Leukocyte Count; Leukocyte Disorders; Leukopenia; Myasthenia Gravis; Pentoxyl; Syringomyelia | 1955 |
[Home chemotherapy by concomitant UFT + Leucovorin (po.) in postoperative colorectal cancer patients assessed with Dukes D and curability C colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Drug Administration | 2004 |
[Complete response to CPT-11 and UFT/LV combination therapy in a case with simultaneous multiple lung metastases from colon cancer].
Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neop | 2006 |
[A case of advanced gastric cancer with multiple liver metastasis successfully treated with combination chemotherapy using UFT, CDDP and etoposide].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration | 1996 |
Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity.
Topics: Anemia; Animals; Cell Line; Cytopathogenic Effect, Viral; Female; HIV; Leukopenia; Mice; Mice, Inbre | 1990 |
Different effect of benzylacyclouridine on the toxic and therapeutic effects of azidothymidine in mice.
Topics: Acquired Immunodeficiency Syndrome; Anemia; Animals; Dose-Response Relationship, Drug; Female; Kinet | 1990 |
[Combination chemotherapy with UFT, etoposide, CDDP, adriamycin (FEPA) in advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 1989 |
[Antitumor activity and toxicity to the immune system and intestine, of the fluorinated pyrimidines FUra, 5'-DFUR, tegafur and UFT].
Topics: Animals; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bone Marro | 1988 |
[Immunosuppression during clinical and experimental organ transplantation].
Topics: Alkylating Agents; Animals; Anti-Bacterial Agents; Antilymphocyte Serum; Blood; Drainage; Electrocar | 1968 |
[The hypoplastic state of hematopoiesis following chemotherapy with alkylating compounds].
Topics: Adult; Aged; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Female; Hematologic Disease | 1969 |
Molecular models for pharmacological tolerance and addiction.
Topics: Adipose Tissue; Animals; Barbiturates; Carboxy-Lyases; Cell Line; Drug Tolerance; Enzyme Activation; | 1971 |